Affichem Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 2

Affichem General Information

Description

Developer of therapeutic molecules and theranostic markers designed to develop and commercialize innovative therapeutic molecules. The company eases the treatment of cancer and neurodegenerative diseases through its developed molecules in the field of cancer and neurodegenerative diseases, development, and commercialization of products for the pharmaceutical industry, helping patients with the treatment of cancers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Corporate Office
  • 9 Saint-joseph Street
  • 31400 Toulouse
  • France

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Affichem Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 01-Dec-2022 00000 Completed Generating Revenue
4. Grant 29-Jun-2012 00.000 00000 Completed Generating Revenue
3. Grant 07-Oct-2011 00.000 00000 Completed Generating Revenue
2. Angel (individual) 17-Nov-2009 $89.3K $159K 00000 Completed Startup
1. Accelerator/Incubator 01-Jun-2002 $70.1K $70.1K Completed Startup
To view Affichem’s complete valuation and funding history, request access »

Affichem Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000 00.000000 000.00 000.00 00 000.00 000
To view Affichem’s complete cap table history, request access »

Affichem Patents

Affichem Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3515453-A1 Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof Pending 22-Sep-2016 000000000
US-20200016177-A1 Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof Inactive 22-Sep-2016 000000000
US-20230138400-A1 Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof Pending 22-Sep-2016 000000000 0
EP-3097904-A1 Depigmenting agents to lighten the skin Active 29-May-2015 0000000000 0
EP-3097904-B1 Depigmenting agents to lighten the skin Active 29-May-2015 C07C217/18 0
To view Affichem’s complete patent history, request access »

Affichem Executive Team (4)

Name Title Board Seat Contact Info
Marc Poirot Ph.D Co-Founder & Board Member
Sandrine Silvente-Poirot Ph.D Co-Founder & Board Member
Stéphane Silvente Co-Founder, Chief Executive Officer, President, Chairman & Directeur General
You’re viewing 3 of 4 executive team members. Get the full list »

Affichem Board Members (4)

Name Representing Role Since
Marc Poirot Ph.D Affichem Co-Founder & Board Member 000 0000
Michaël Paillasse Ph.D Self Board Member 000 0000
Sandrine Silvente-Poirot Ph.D Affichem Co-Founder & Board Member 000 0000
You’re viewing 3 of 4 board members. Get the full list »

Affichem Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Affichem Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
European Commission Government 000 0000 000000 0
L'Agence Nationale de la Recherche Government 000 0000 000000 0
To view Affichem’s complete investors history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »